Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of AC-083 in healthy male subjects
NCT02719197Phase 1Completed
- Sponsor
- Idorsia
- Start
- Feb 2016
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in epilepsy and essential tremor (ET) comparing AC-083 SAD with Placebo SAD (2 arms). Primary endpoints: Number of participants with adverse events (AEs), Changes from baseline in supine blood pressure and 2 more. Started Feb 2016; status: completed.
02
Drugs
NBI-827104
03
Conditions
epilepsyessential tremor (ET)
Beyond the preview
Go deeper on NCT02719197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02719197.